Bluejay Diagnostics (BJDX) Equity Average (2020 - 2026)

Bluejay Diagnostics' Equity Average history runs 7 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Equity Average rose 5.84% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (up 5.84% YoY), while the FY2025 annual figure was $5.9 million, up 35.72% from the prior year.
• Equity Average came in at $5.1 million for Q1 2026 at Bluejay Diagnostics, up from $4.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $19.4 million in Q1 2022 to a low of $3.1 million in Q1 2024.
• A 5-year average of $8.2 million and a median of $6.0 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average soared 3282.33% in 2022 and tumbled 69.76% in 2024, its largest moves.
• Bluejay Diagnostics' Equity Average stood at $12.7 million in 2022, then slumped by 68.02% to $4.1 million in 2023, then jumped by 59.03% to $6.4 million in 2024, then declined by 25.02% to $4.8 million in 2025, then increased by 5.05% to $5.1 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $5.1 million, $4.8 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison